Valeant Inks Deal To Divest INova Pharmaceuticals For $930M
Zacks Investment Research | Jun 12, 2017 04:49AM ET
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group (NASDAQ:CG).
Shares of Valeant Pharma have underperformed the Zacks classified Medical-Drugs industry year to date. The stock lost 13.8% as against the industry’s gain of 3.4%.
In fact, this deal is a part of company’s strategy to strengthen its balance sheet and simplify its operating model. Valeant Pharma will utilize the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility. The sale is expected to complete in the second half of 2017, subject to customary closing conditions, and the receipt of regulatory approvals.
Debt reduction continues to be a priority for Valeant Pharma, and as of May 9, 2017 the company reduced the principal amount of its debt by $3.6 billion since first quarter of 2016. This includes $1.3 billion of debt retired in the quarter along with proceeds from the non-core asset sales, including the sale of three skincare franchises to L'Oreal, which closed on Mar 3, 2017.
iNova markets prescription and over-the-counter products in areas such as weight management, pain management, cardiology, and cough and cold. Moreover, the company has a leading market position in Australia and South Africa and also has an established platform in Asia.
Notably, Valeant Pharma acquired iNova from Australian private equity firms Archer Capital and Ironbridge in Dec 2011 and paid 625 million Australian dollars as upfront payment to shareholders of iNova.
Zacks Rank and Stocks to Consider
Valeant Pharma carries a Zacks Rank #3 (Hold). Better-ranked stocks in health care sector include VIVUS, Inc. (NASDAQ:VVUS) , MEI Pharma, Inc. (NASDAQ:MEIP) and Sanofi (NYSE:SNY) . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Sanofi carries a Zacks Rank #2 (Buy). You can see .
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all four trailing quarters, with an average beat of 233.69%. The share price of the company increased 4.4% year to date.
Get The News You Want
MEI Pharma’s estimates moved up from loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%. The share price of the company increased 26.4% year to date.
Sanofi’s earnings per share estimates increased from $3.26 to $3.30 for 2018 over last 30 days. The company posted positive earnings surprises in three of the last four trailing quarters, with an average beat of 5.10%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.